Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Operating Income: 2009-2024

Historic Operating Income for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to -$22.6 million.

  • Ligand Pharmaceuticals' Operating Income rose 1647.73% to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 207.32%. This contributed to the annual value of -$22.6 million for FY2024, which is 289.30% down from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Operating Income is -$22.6 million, which was down 289.30% from $11.9 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Operating Income high stood at $103.9 million for FY2021, and its period low was -$22.6 million during FY2024.
  • Over the past 3 years, Ligand Pharmaceuticals' median Operating Income value was $3.0 million (recorded in 2022), while the average stood at -$2.5 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Operating Income surged by 293.22% in 2023, and later crashed by 289.30% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Operating Income (Yearly) stood at $37.5 million in 2020, then spiked by 176.94% to $103.9 million in 2021, then crashed by 97.08% to $3.0 million in 2022, then spiked by 293.22% to $11.9 million in 2023, then tumbled by 289.30% to -$22.6 million in 2024.